ArticleCancers2024

Tolerability and Preliminary Outcomes of Adjuvant T-DM1 in HER2-Positive Breast Cancer After Neoadjuvant Therapy: The ATD Study.

Eriseld Krasniqi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.